Fig. 5: CD40 competitively bound TRAFs with STING. | Cancer Gene Therapy

Fig. 5: CD40 competitively bound TRAFs with STING.

From: Characterization of tertiary lymphoid structure identifies competitive binding of CD40 and STING with TRAF2 driving IRF4-mediated B cell activation in esophageal squamous cell carcinoma

Fig. 5

A Co-immunoprecipitation (co-IP) of CD40 or STING. B Co-IP using anti-TRAF2 to pull down STING and immunoblot (IB) detection of CD40 and STING molecules. C Multiplex immunofluorescence demonstrated the interactions of CD40 and STING with TRAF2 (scale bar = 100 μm). D Impact of CD40 and STING stimulation in the NF-κB pathway. E Flow cytometry revealed the degrees of B cell differentiation under different stimuli (APC-CD19, PE-pre-BCR).

Back to article page